Biotechnology company TScan Therapeutics Inc. announced last week that the first patient in the phase 1 clinical trial had been dosed with its new TCR-T therapy to treat solid tumours. TScan Therapeutics will soon provide data on the progress of its TCR-T experiments, which could attract investor attention.
The commencement of clinical trials marks a...
IPO intraday trading strategy idea
The share price is falling and gonna continue this trend today.
The demand for shares of the company still looks lower than the supply.
These and other conditions can cause a fall in the share price today.
So I opened a short position from $10,88;
stop-loss — $12,28
take-profit — $6,68/MOC price
Do not view this idea as a...